{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"103.6200","value":"74.3700"},{"groupId":"OG001","spread":"98.8909","value":"30.2546"},{"groupId":"OG002","spread":"53.1457","value":"10.7795"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 1 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.4783","value":"92.1105"},{"groupId":"OG001","spread":"48.9060","value":"32.1430"},{"groupId":"OG002","spread":"78.4507","value":"20.7386"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"63.4941","value":"101.0003"},{"groupId":"OG001","spread":"101.8080","value":"84.2143"},{"groupId":"OG002","spread":"192.7165","value":"116.3071"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Cycle 2 Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.7578","value":"64.9807"},{"groupId":"OG001","spread":"161.3495","value":"131.5277"},{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG002","spread":"NA","value":"26.9231"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Cycle 3 Day 1"},{"categories":[{"measurements":[{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG000","spread":"NA","value":"-8.3636"},{"groupId":"OG001","spread":"54.8320","value":"50.2904"},{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG002","spread":"NA","value":"21.4744"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"Cycle 4 Day 1"},{"categories":[{"measurements":[{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG000","spread":"NA","value":"64"},{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG001","spread":"NA","value":"50.4363"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 5 Day 1"},{"categories":[{"measurements":[{"comment":"Here, 'NA' indicates that standard deviation was not calculated due to the presence of only one participant at this specific time point.","groupId":"OG000","spread":"NA","value":"67.8182"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 7 Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Change in ctDNA is defined as the percentage change in ctDNA from baseline to each timepoint for the safety population. This outcome measure was assessed only for substudy 1 Part A.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"AZD8853 300 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"AZD8853 1000 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"AZD8853 3000 mg"}],"paramType":"MEAN","populationDescription":"Safety set included all participants who received any amount of IP. Here, \"number of participants analyzed\" specifies all participants who were evaluated for this outcome measure and \"n\" (number analyzed in each raw) signifies the participants with available data that were analyzed for each timepoint for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline (pre-treatment), Day 8 of Cycle 1, Days 1 and 8 of Cycle 2, Day 1 of Cycles 3, 4, 5, 7 (each cycle is equal to 21 days)","title":"Percentage Change in Circulating Tumor Deoxyribonucleic Acid (ctDNA) Levels From Baseline","type":"SECONDARY","unitOfMeasure":"Percentage change from baseline in ctDNA"}